Vanguard Group Inc. Has $78.81 Million Stock Holdings in Bausch Health Cos Inc. $BHC

Vanguard Group Inc. increased its holdings in shares of Bausch Health Cos Inc. (NYSE:BHC) by 4.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,241,072 shares of the company’s stock after purchasing an additional 470,968 shares during the period. Vanguard Group Inc. owned approximately 3.30% of Bausch Health Cos worth $78,808,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Paulson & CO. Inc. boosted its holdings in shares of Bausch Health Cos by 24.0% during the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after buying an additional 6,352,667 shares in the last quarter. Goldentree Asset Management LP increased its stake in shares of Bausch Health Cos by 13.2% in the 2nd quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock valued at $227,848,000 after acquiring an additional 4,004,889 shares in the last quarter. MUFG Securities EMEA plc acquired a new position in shares of Bausch Health Cos during the 2nd quarter valued at $22,644,000. SG Americas Securities LLC boosted its stake in Bausch Health Cos by 114.4% during the second quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after acquiring an additional 3,282,684 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. increased its stake in Bausch Health Cos by 14.9% in the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after purchasing an additional 1,010,987 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $5.56 on Friday. The firm has a market capitalization of $2.06 billion, a P/E ratio of 13.24 and a beta of 0.37. The company has a quick ratio of 1.08, a current ratio of 1.47 and a debt-to-equity ratio of 54.68. The stock’s 50-day simple moving average is $6.41 and its two-hundred day simple moving average is $6.64. Bausch Health Cos Inc. has a twelve month low of $4.25 and a twelve month high of $8.69.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing the consensus estimate of $1.21 by ($0.13). The company had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.71 billion. Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%. As a group, equities analysts anticipate that Bausch Health Cos Inc. will post 4.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Weiss Ratings downgraded shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a report on Thursday, February 19th. Barclays decreased their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Finally, Truist Financial boosted their target price on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research note on Wednesday, January 7th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $8.33.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.